Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1963 1
1964 3
1965 1
1966 1
1968 2
1969 2
1971 3
1972 4
1973 4
1974 2
1975 6
1976 3
1977 10
1978 4
1979 11
1980 18
1981 15
1982 24
1983 29
1984 32
1985 58
1986 57
1987 70
1988 77
1989 99
1990 132
1991 157
1992 191
1993 211
1994 207
1995 270
1996 319
1997 407
1998 434
1999 549
2000 607
2001 712
2002 837
2003 1000
2004 1264
2005 1582
2006 1934
2007 2065
2008 2269
2009 2576
2010 3005
2011 3236
2012 3622
2013 4090
2014 4166
2015 4275
2016 4209
2017 4094
2018 4380
2019 4537
2020 3822
2021 2839
2022 834
2023 569
2024 1407
2025 8

Text availability

Article attribute

Article type

Publication date

Search Results

60,138 results

Results by year

Filters applied: . Clear all
Page 1
Comparing the efficacy of pharmacological and psychological treatment, alone and in combination, in children and adolescents with obsessive-compulsive disorder: A network meta-analysis.
Tao Y, Li H, Li L, Zhang H, Xu H, Zhang H, Zou S, Deng F, Huang L, Wang Y, Wang X, Tang X, Fu X, Yin L. Tao Y, et al. Among authors: li h, li l. J Psychiatr Res. 2022 Apr;148:95-102. doi: 10.1016/j.jpsychires.2022.01.057. Epub 2022 Jan 29. J Psychiatr Res. 2022. PMID: 35121274 Review.
The primary outcome was change in symptom severity as a result of treatment, as assessed using the Yale-Brown Obsessive Compulsive Scale (YBOCS) or Children's Yale-Brown Obsessive Compulsive Scale (CY-BOCS). RESULTS: We included 18 studies with 1353 participants and 12 kin …
The primary outcome was change in symptom severity as a result of treatment, as assessed using the Yale-Brown Obsessive Compulsive Scale (YB …
ApoE attenuates unresolvable inflammation by complex formation with activated C1q.
Yin C, Ackermann S, Ma Z, Mohanta SK, Zhang C, Li Y, Nietzsche S, Westermann M, Peng L, Hu D, Bontha SV, Srikakulapu P, Beer M, Megens RTA, Steffens S, Hildner M, Halder LD, Eckstein HH, Pelisek J, Herms J, Roeber S, Arzberger T, Borodovsky A, Habenicht L, Binder CJ, Weber C, Zipfel PF, Skerka C, Habenicht AJR. Yin C, et al. Among authors: li y. Nat Med. 2019 Mar;25(3):496-506. doi: 10.1038/s41591-018-0336-8. Epub 2019 Jan 28. Nat Med. 2019. PMID: 30692699 Free PMC article.
Non-equivalence of Wnt and R-spondin ligands during Lgr5+ intestinal stem-cell self-renewal.
Yan KS, Janda CY, Chang J, Zheng GXY, Larkin KA, Luca VC, Chia LA, Mah AT, Han A, Terry JM, Ootani A, Roelf K, Lee M, Yuan J, Li X, Bolen CR, Wilhelmy J, Davies PS, Ueno H, von Furstenberg RJ, Belgrader P, Ziraldo SB, Ordonez H, Henning SJ, Wong MH, Snyder MP, Weissman IL, Hsueh AJ, Mikkelsen TS, Garcia KC, Kuo CJ. Yan KS, et al. Among authors: li x. Nature. 2017 May 11;545(7653):238-242. doi: 10.1038/nature22313. Epub 2017 May 3. Nature. 2017. PMID: 28467820 Free PMC article.
Immunotherapy of non-Hodgkin's lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor-modified T cells.
Turtle CJ, Hanafi LA, Berger C, Hudecek M, Pender B, Robinson E, Hawkins R, Chaney C, Cherian S, Chen X, Soma L, Wood B, Li D, Heimfeld S, Riddell SR, Maloney DG. Turtle CJ, et al. Among authors: li d. Sci Transl Med. 2016 Sep 7;8(355):355ra116. doi: 10.1126/scitranslmed.aaf8621. Sci Transl Med. 2016. PMID: 27605551 Free PMC article. Clinical Trial.
We conducted a clinical trial in which CD19 CAR-T cells were manufactured from defined T cell subsets and administered in a 1:1 CD4(+)/CD8(+) ratio of CAR-T cells to 32 adults with relapsed and/or refractory B cell non-Hodgkin's lymphoma after cyclophosphamide (Cy)-based l …
We conducted a clinical trial in which CD19 CAR-T cells were manufactured from defined T cell subsets and administered in a 1:1 CD4(+)/CD8(+ …
Busulfan Plus Cyclophosphamide Versus Total Body Irradiation Plus Cyclophosphamide for Adults Acute B Lymphoblastic Leukemia: An Open-Label, Multicenter, Phase III Trial.
Zhang H, Fan Z, Huang F, Han L, Xu Y, Xu N, Deng L, Wang S, Lin D, Luo X, Zhang Q, Liu X, Li X, Liang X, Xie S, Qu H, Yu S, Zhou H, Shi P, Xuan L, Lin R, Liu H, Jin H, Sun J, Liu Q. Zhang H, et al. Among authors: li x. J Clin Oncol. 2023 Jan 10;41(2):343-353. doi: 10.1200/JCO.22.00767. Epub 2022 Sep 9. J Clin Oncol. 2023. PMID: 36084276 Free PMC article. Clinical Trial.
We investigated the efficacy and toxicity of busulfan plus cyclophosphamide (BuCy) and TBI plus cyclophosphamide (TBI-Cy) conditioning in allo-HSCT for adult standard-risk B-cell-ALL in first complete remission (CR1). ...CONCLUSION: The BuCy regimen has noninferior efficie …
We investigated the efficacy and toxicity of busulfan plus cyclophosphamide (BuCy) and TBI plus cyclophosphamide (TBI-Cy) conditionin …
Hematopoietic stem cells: multiparameter regulation.
Song K, Li L, Wang Y, Liu T. Song K, et al. Among authors: li l. Hum Cell. 2016 Apr;29(2):53-7. doi: 10.1007/s13577-016-0134-x. Epub 2016 Feb 16. Hum Cell. 2016. PMID: 26883144 Review.
Pairing of single-cell RNA analysis and T cell antigen receptor profiling indicates breakdown of T cell tolerance checkpoints in atherosclerosis.
Wang Z, Zhang X, Lu S, Zhang C, Ma Z, Su R, Li Y, Sun T, Li Y, Hong M, Deng X, Monjezi MR, Hristov M, Steffens S, Santovito D, Dornmair K, Ley K, Weber C, Mohanta SK, Habenicht AJR, Yin C. Wang Z, et al. Among authors: li y. Nat Cardiovasc Res. 2023 Mar;2(3):290-306. doi: 10.1038/s44161-023-00218-w. Epub 2023 Feb 23. Nat Cardiovasc Res. 2023. PMID: 37621765 Free PMC article.
Renewed proliferation in adult mouse cochlea and regeneration of hair cells.
Shu Y, Li W, Huang M, Quan YZ, Scheffer D, Tian C, Tao Y, Liu X, Hochedlinger K, Indzhykulian AA, Wang Z, Li H, Chen ZY. Shu Y, et al. Among authors: li w, li h. Nat Commun. 2019 Dec 4;10(1):5530. doi: 10.1038/s41467-019-13157-7. Nat Commun. 2019. PMID: 31797926 Free PMC article.
2-(6-Chloro-1H-indol-3-yl)acetonitrile.
Li JF, Luo YH. Li JF, et al. Acta Crystallogr Sect E Struct Rep Online. 2012 Jan;68(Pt 1):o144. doi: 10.1107/S1600536811053372. Epub 2011 Dec 17. Acta Crystallogr Sect E Struct Rep Online. 2012. PMID: 22259430 Free PMC article.
In the title compound, C(10)H(7)ClN(2), the carbonitrile group is twisted away from the plane of the indole ring system [C(cy)-C(me)-C(ar)-C(ar) = -44.7 (8); cy = cyanide, me = methyl-ene and ar = aromatic]. ...
In the title compound, C(10)H(7)ClN(2), the carbonitrile group is twisted away from the plane of the indole ring system [C(cy)-C(me)- …
60,138 results
You have reached the last available page of results. Please see the User Guide for more information.